Scancell Holdings PLC, the developer of novel immunotherapies for the treatment of cancer and infectious disease, has expanded its R&D capabilities by taking new laboratory and office space in the Bellhouse Building at The Oxford Science Park, one of the UK’s leading parks for science and technology companies.
The new premises, which are complementary to Scancell’s laboratories in the Biodiscovery Institute at the University of Nottingham, will allow the company to further accelerate the development of its portfolio of immunotherapies.
Scancell, which raised £46 million last year to drive its pipeline through clinical trials, is now working from 1,900 sq ft of laboratory space and 1,800 sq ft of office facilities at the science park. Scancell currently employs just over 40 staff, of which approximately half are located in the new premises and plans to recruit additional people to its clinical and product development teams in the next 12 months.
The company is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with innovative products in multiple cancer indications and a vaccine in development for COVID-19.
The new laboratories will support the company’s clinical trial activities and provide analytical and formulation facilities for future product development.
Professor Lindy Durrant, Chief Executive Officer of Scancell, said: “The Oxford Science Park is the perfect location for Scancell’s expansion, with access to an excellent local talent pool as we grow the business. We are excited to be part of the creative and collaborative group of companies located in the Park and look forward to further developing our innovative products at this new site.”
Rory Maw, CEO of The Oxford Science Park, said: “We are delighted that Scancell has chosen to locate its new R&D facility at The Oxford Science Park, the Company’s first laboratories outside of the university setting. Scancell joins Enara Bio, MoA Technology and Sitryx in the Bellhouse Building.
"With its leading research in cancer and infectious disease, the Company is a great addition to the innovation community here. This is exciting news for TOSP, following the announcement of our partnership with GIC to accelerate development of the Park.”
